Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 5/20 | 0.44 |
| ▸ | HRH1 | P35367 | 5/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 6/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226924 | 0.84 | KCNA3 (0.65) | KCNA3HRH2HRH1CTSKCACNA1B | |
| SCHEMBL5232122 | 0.80 | GPR119 (0.41) | HRH2HRH1NSD2 | |
| SCHEMBL5234934 | 0.79 | HRH2 (0.41) | HRH2HRH1CACNA1B | |
| SCHEMBL1714253 | 0.73 | HRH2 (0.68) | KCNA3HRH2HRH1CTSK | |
| SCHEMBL5240611 | 0.72 | CACNA1B (0.33) | CACNA1B | |
| SCHEMBL25700736 | 0.71 | CTSK (0.51) | KCNA3HRH2HRH1CTSKCCR5 | |
| SCHEMBL5218948 | 0.71 | HRH2 (0.68) | HRH2HRH1 | |
| SCHEMBL20689233 | 0.70 | CTSK (0.62) | KCNA3HRH2HRH1CTSKCCR5 | |
| SCHEMBL13583442 | 0.70 | CTSK (0.54) | KCNA3HRH2HRH1CTSKCCR5 | |
| SCHEMBL28249233 | 0.70 | CTSK (0.54) | KCNA3HRH2HRH1CTSKCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1254895-B1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | KCNA3 278/4885HRH2 66/4885HRH1 63/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | KCNA3 225/4885HRH2 62/4885HRH1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.